Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01905722 · ClinicalTrials.gov registry record · NA
Development of Novel Therapies for NIDDM
A NA study of Metabolism, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 64
- Enrollment target
- 1
- Study location
NCT01905722: Completed NA study of Metabolism, sponsored by Duke University.
NCT01905722 is a NA study of Metabolism that has completed, run by Duke University. The registered enrollment target is 64 participants, below the 13,262-participant average among 19 other Metabolism trials with a reported enrollment target (100% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01905722, a NA study of Metabolism, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 64 participants
- Enrollment target
- 1
- Study location
Study Summary
The overarching goal of this program project grant is the development of technologies that lead to new methods for studying, detecting, and treating type 2 diabetes, and their integration with hypothesis-driven diabetes research projects. Project 4 of the grant, led by Dr. Craig Malloy at UTSW, will develop and apply new technology in MRI to test core hypotheses about the development of insulin resistance in people. The long-term goal is to develop technology to monitor metabolism in skeletal muscle, brain and the liver using magnetic resonance imaging (MRI) and magnetic resonance spectroscopy (MRS) in a 3 Tesla and 7 Tesla MRI scanners. These advanced imaging methods allow researchers to take pictures of the inside of the body and to measure metabolism as it occurs in the MRI scanner. Standard clinical MRI for medical diagnosis and treatment is performed in a 1 Tesla or 3 Tesla MRI scanner. A primary goal of the 7 Tesla research program is to develop a group of protocols for investigating specific metabolic pathways in adipose (fat) tissue, skeletal muscle and the liver. This study is being done to improve methods of imaging and measuring molecules in a 3 Tesla or 7 Tesla scanners.
Primary Outcome
The primary outcome measure will be the identification of metabolic tracers that will yield optimal data to apply to disease processes in future metabolic studies.
Conditions Studied
Interventions
- OTHER 3 Tesla
- OTHER 7 Tesla
Study Locations (1)
Texas
- University of Texas Southwestern Medical Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 64 participants |
| Start Date | 2013-12-10 |
| Est. Completion | 2017-05-17 |
| Phase | NA |
What the finished NCT01905722 record still lists
NCT01905722 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 64 participants, a relatively small participant target, below the 13,262-participant average among 19 other Metabolism trials with a reported enrollment target (100% lower).
The record links to 1 condition, with Metabolism appearing as the primary indexed condition, and to 2 interventions - of which 3 Tesla is the first listed.
NCT01905722 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT01905722 about?
NCT01905722 is a clinical study titled "Development of Novel Therapies for NIDDM". The overarching goal of this program project grant is the development of technologies that lead to new methods for studying, detecting, and treating type 2 diabetes, and their integration with hypothesis-driven diabetes research projects. Project 4 of the grant, led by Dr. Craig Malloy at UTSW, wil...
What is the current status of trial NCT01905722?
This trial is currently completed. It is a NA study. The enrollment target is 64 participants. The study started on 2013-12-10. Estimated completion is 2017-05-17.
What conditions does trial NCT01905722 study?
This clinical trial studies the following conditions: Metabolism.
What interventions are being tested in trial NCT01905722?
The interventions under investigation include: 3 Tesla (OTHER), 7 Tesla (OTHER).
Who is sponsoring clinical trial NCT01905722?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01905722 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metabolism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01905722's enrollment target sits among peer trials
64 6th of 19 higher than 13 of 19 other Metabolism trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metabolism trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
GLYLO Supplement Pilot Trial on Glycation and Aging in Postmenopausal Women
RECRUITING · NA
-
Tracing Of Real-time glu13Cose Metabolism in Human Immune Cells
RECRUITING · NA
-
Personalized Responses to Dietary Composition Trial 3
RECRUITING · NA
-
Study of Clinical Response to Acute Metformin By Leveraging Evaluations During a Mixed Meal Tolerance Test for Exploring Glycemia and GeneticS
ACTIVE NOT RECRUITING · NA
-
Duration of Physical Inactivity and Postprandial Lipid Metabolism
COMPLETED · NA
-
Effects of a Caffeine- and Protein-Containing Coffee Beverage on Metabolism and Muscular Performance
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01853631 · 64 participants · Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
- NCT03739502 · 64 participants · Phase 2
A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant
- NCT03739814 · 64 participants · Phase 2
Inotuzumab Ozogamicin and Blinatumomab With or Without Ponatinib in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia
- NCT03866408 · 64 participants · Early Phase 1
Insulin Regulation of Lipolysis and Lipolysis Proteins
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI